StockNews.com began coverage on shares of Madrigal Pharmaceuticals (NASDAQ:MDGL – Free Report) in a research note published on Thursday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Several other research analysts have also recently commented on the company. Canaccord Genuity Group reissued a buy rating and set a $336.00 price target on […]
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Rating) was up 3.1% on Wednesday . The company traded as high as $211.90 and last traded at $210.25. Approximately 96,093 shares were traded during trading, a decline of 75% from the average daily volume of 391,106 shares. The stock had previously closed at $203.88. Analysts Set New Price […]
StockNews.com cut shares of Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Rating) from a hold rating to a sell rating in a research report released on Monday morning. MDGL has been the subject of several other research reports. Oppenheimer upped their price objective on Madrigal Pharmaceuticals from $300.00 to $350.00 in a report on Tuesday, May 16th. […]
StockNews.com cut shares of Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Rating) from a hold rating to a sell rating in a research note issued to investors on Monday morning. Several other analysts have also recently commented on the company. Oppenheimer upped their target price on Madrigal Pharmaceuticals from $300.00 to $350.00 in a report on Tuesday, […]
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Rating) was the target of a significant growth in short interest in April. As of April 15th, there was short interest totalling 1,480,000 shares, a growth of 19.4% from the March 31st total of 1,240,000 shares. Currently, 10.8% of the shares of the stock are sold short. Based on […]